Osteopontin affects the persistence of beta-glucan-induced hepatic granuloma formation and tissue injury through two distinct mechanisms.
D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002465:Cell Movement / Q000187:drug effects; D056486:Chemical and Drug Induced Liver Injury; D018925:Chemokines / Q000378:metabolism; D003713:Dendritic Cells / Q000276:immunology; D015870:Gene Expression; D005936:Glucans; D006099:Granuloma / Q000139:chemically induced / Q000235:genetics / Q000276:immunology*; D008107:Liver Diseases / Q000276:immunology* / Q000473:pathology; D008198:Lymph Nodes / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D053495:Osteopontin; D012333:RNA, Messenger / Q000378:metabolism; D012795:Sialoglycoproteins / Q000235:genetics / Q000378:metabolism / Q000502:physiology*
D018925:Chemokines; D005936:Glucans; D012333:RNA, Messenger; D012795:Sialoglycoproteins; C506896:Spp1 protein, mouse; D053495:Osteopontin